NCT06160609View on ClinicalTrials.gov

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Belantamab Mafodotin

Belantamab Mafodotin will be administered.

DRUG

GSK3174998

GSK3174998 will be administered.

Trial Locations (3)

3065

GSK Investigational Site, Fitzroy

M5G 2M9

GSK Investigational Site, Toronto

SE-141 86

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06160609 - Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | Biotech Hunter | Biotech Hunter